Scientists have uncovered new genetic rules that determine whether the immune system’s “killer” T cells remain powerful long-term defenders or become worn out and ineffective. By building a detailed ...
CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...
The generation of durable CD8+ T cell memory following infection or vaccination is essential for protection against future encounters with the same or related pathogens. This process has traditionally ...
Clonally expanded CD8+ T cells are key drivers of alopecia areata, mediating epithelial cell death and immune infiltration. JAK inhibitors are approved for AA treatment, but recurrence is common, ...
Collaborative research defines the FOXO1-KLHL6 axis as a novel therapeutic target to enhance T cell-mediated immune response against tumors CD8⁺ T cells are the frontline soldiers of the body against ...
A new study has uncovered new genetic rules that determine how CD8 “killer” T cells choose between becoming long-lasting, protective immune cells or slipping into exhausted, dysfunctional states.
Meet the Jekyll and Hyde of the immune system: activated CD8⁺ T cells. On June 24 in Nature Immunology, researchers led by Dorian McGavern at the National Institutes of Health introduce a granzyme ...
Killer immune cells destroy cancer cells and cells infected by virus. These CD8 + T cells are activated after detection of viral infection or growth of "non-self" tumor cells. However, in chronic ...
WEHI scientists have uncovered a promising new way to enhance the effectiveness of vaccines by tapping into the potential of a specific type of immune cell, opening the door to long-lasting vaccines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results